Effect of recombinant human interleukin 4 on human monocyte activity

Melissa M. Hudson, Avi B. Markowitz, Jordan U. Gutterman, Rebecca D. Knowles, John S. Snyder, Avi Markowitz

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Recombinant human interleukin 4 (rhuIL-4), a lymphokine that reportedly stimulates tumoricidal activity in mouse macrophages, is currently undergoing clinical studies to determine its efficacy in the treatment of cancer. IL-4 is known to participate with other cytokines to regulate growth and differentiation of various hematopoietic cells as well as modulate the immune response. Little is known about the effect of rhuIL-4 on human monocyte tumoricidal activity. The purpose of these studies was to examine the effect of rhuIL-4 on human peripheral blood monocytes. Peripheral blood monocytes isolated from normal donors failed to demonstrate tumoricidal activity or interleukin 1 secretion after treatment with rhuIL-4 in vitro. Furthermore, monocyte-mediated cytotoxicity induced by recombinant human γ-interferon plus muramyl dipeptide was suppressed in a dose-dependent manner by rhuIL-4. This reduction in cytotoxicity corresponded to a reduction in IL-1 production and secretion. Further investigation of rhuIL-4 and its role in the cytokine network is necessary for the development of effective immunotherapy in cancer patients.

Original languageEnglish (US)
Pages (from-to)3154-3158
Number of pages5
JournalCancer Research
Volume50
Issue number11
StatePublished - Jun 1 1990
Externally publishedYes

Fingerprint

Human Activities
Interleukin-4
Monocytes
Interleukin-1
Acetylmuramyl-Alanyl-Isoglutamine
Cytokines
Lymphokines
Immunotherapy
Interferons
Neoplasms
Macrophages
Tissue Donors
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hudson, M. M., Markowitz, A. B., Gutterman, J. U., Knowles, R. D., Snyder, J. S., & Markowitz, A. (1990). Effect of recombinant human interleukin 4 on human monocyte activity. Cancer Research, 50(11), 3154-3158.

Effect of recombinant human interleukin 4 on human monocyte activity. / Hudson, Melissa M.; Markowitz, Avi B.; Gutterman, Jordan U.; Knowles, Rebecca D.; Snyder, John S.; Markowitz, Avi.

In: Cancer Research, Vol. 50, No. 11, 01.06.1990, p. 3154-3158.

Research output: Contribution to journalArticle

Hudson, MM, Markowitz, AB, Gutterman, JU, Knowles, RD, Snyder, JS & Markowitz, A 1990, 'Effect of recombinant human interleukin 4 on human monocyte activity', Cancer Research, vol. 50, no. 11, pp. 3154-3158.
Hudson MM, Markowitz AB, Gutterman JU, Knowles RD, Snyder JS, Markowitz A. Effect of recombinant human interleukin 4 on human monocyte activity. Cancer Research. 1990 Jun 1;50(11):3154-3158.
Hudson, Melissa M. ; Markowitz, Avi B. ; Gutterman, Jordan U. ; Knowles, Rebecca D. ; Snyder, John S. ; Markowitz, Avi. / Effect of recombinant human interleukin 4 on human monocyte activity. In: Cancer Research. 1990 ; Vol. 50, No. 11. pp. 3154-3158.
@article{016fa0f36acf4dd09e43610de3626ebf,
title = "Effect of recombinant human interleukin 4 on human monocyte activity",
abstract = "Recombinant human interleukin 4 (rhuIL-4), a lymphokine that reportedly stimulates tumoricidal activity in mouse macrophages, is currently undergoing clinical studies to determine its efficacy in the treatment of cancer. IL-4 is known to participate with other cytokines to regulate growth and differentiation of various hematopoietic cells as well as modulate the immune response. Little is known about the effect of rhuIL-4 on human monocyte tumoricidal activity. The purpose of these studies was to examine the effect of rhuIL-4 on human peripheral blood monocytes. Peripheral blood monocytes isolated from normal donors failed to demonstrate tumoricidal activity or interleukin 1 secretion after treatment with rhuIL-4 in vitro. Furthermore, monocyte-mediated cytotoxicity induced by recombinant human γ-interferon plus muramyl dipeptide was suppressed in a dose-dependent manner by rhuIL-4. This reduction in cytotoxicity corresponded to a reduction in IL-1 production and secretion. Further investigation of rhuIL-4 and its role in the cytokine network is necessary for the development of effective immunotherapy in cancer patients.",
author = "Hudson, {Melissa M.} and Markowitz, {Avi B.} and Gutterman, {Jordan U.} and Knowles, {Rebecca D.} and Snyder, {John S.} and Avi Markowitz",
year = "1990",
month = "6",
day = "1",
language = "English (US)",
volume = "50",
pages = "3154--3158",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Effect of recombinant human interleukin 4 on human monocyte activity

AU - Hudson, Melissa M.

AU - Markowitz, Avi B.

AU - Gutterman, Jordan U.

AU - Knowles, Rebecca D.

AU - Snyder, John S.

AU - Markowitz, Avi

PY - 1990/6/1

Y1 - 1990/6/1

N2 - Recombinant human interleukin 4 (rhuIL-4), a lymphokine that reportedly stimulates tumoricidal activity in mouse macrophages, is currently undergoing clinical studies to determine its efficacy in the treatment of cancer. IL-4 is known to participate with other cytokines to regulate growth and differentiation of various hematopoietic cells as well as modulate the immune response. Little is known about the effect of rhuIL-4 on human monocyte tumoricidal activity. The purpose of these studies was to examine the effect of rhuIL-4 on human peripheral blood monocytes. Peripheral blood monocytes isolated from normal donors failed to demonstrate tumoricidal activity or interleukin 1 secretion after treatment with rhuIL-4 in vitro. Furthermore, monocyte-mediated cytotoxicity induced by recombinant human γ-interferon plus muramyl dipeptide was suppressed in a dose-dependent manner by rhuIL-4. This reduction in cytotoxicity corresponded to a reduction in IL-1 production and secretion. Further investigation of rhuIL-4 and its role in the cytokine network is necessary for the development of effective immunotherapy in cancer patients.

AB - Recombinant human interleukin 4 (rhuIL-4), a lymphokine that reportedly stimulates tumoricidal activity in mouse macrophages, is currently undergoing clinical studies to determine its efficacy in the treatment of cancer. IL-4 is known to participate with other cytokines to regulate growth and differentiation of various hematopoietic cells as well as modulate the immune response. Little is known about the effect of rhuIL-4 on human monocyte tumoricidal activity. The purpose of these studies was to examine the effect of rhuIL-4 on human peripheral blood monocytes. Peripheral blood monocytes isolated from normal donors failed to demonstrate tumoricidal activity or interleukin 1 secretion after treatment with rhuIL-4 in vitro. Furthermore, monocyte-mediated cytotoxicity induced by recombinant human γ-interferon plus muramyl dipeptide was suppressed in a dose-dependent manner by rhuIL-4. This reduction in cytotoxicity corresponded to a reduction in IL-1 production and secretion. Further investigation of rhuIL-4 and its role in the cytokine network is necessary for the development of effective immunotherapy in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0025365457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025365457&partnerID=8YFLogxK

M3 - Article

C2 - 2334911

AN - SCOPUS:0025365457

VL - 50

SP - 3154

EP - 3158

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 11

ER -